ALKEMNSEAlkem Laboratories Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Fri, 26 Dec, 2025 · 18:24 IST

Alkem Labs gets Kerala GST demand order of about Rs 3.82 lakh, to appeal

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.0%Reaction day
₹5537.00
prior close
₹5573.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.4%-0.6% vs market
Pharmaceuticals peers, median of 153sector-0.8%-0.2% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.0
10m
-0.8
15m
-0.6
30m
-0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.0-0.4-0.6-0.8-0.2
Next day
-1.9-0.6-1.3-1.0-0.9
2d
-1.2+0.4-1.6-0.1-1.1
3d
-1.3+0.8-2.1-0.2-1.1
4d
+0.9+1.7-0.9+0.7+0.2
5d
+0.6+1.6-1.1+0.3+0.3
1w
+4.6+1.9+2.7+1.6+3.0
15d
+2.4-3.9+6.3-5.9+8.4
1m
+3.2-3.2+6.4-7.8+10.9
2m
+0.8-3.2+4.0-8.6+9.4
3m
-4.3-12.4+8.2-16.7+12.4
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories received a GST demand order from the Kerala State Tax Officer for FY 2021-22. The order asks for GST of Rs 2.05 lakh, penalty of Rs 41,019, and interest of Rs 1.36 lakh, totalling about Rs 3.82 lakh, alleging excess claim of Input Tax Credit. The company disagrees with the demand and plans to file an appeal. Management states there is no material impact on financials or operations.

Likely market impact

Small tax demand that the company is contesting via appeal; no material financial or operational impact expected.